Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE₂ signaling pathway in mice.

ABSTRACT:

Introduction

Lung cancer is characterized by a poor prognosis and is a significant comorbidity of chronic obstructive pulmonary disease (COPD). Therefore, effective chemopreventive agents are warranted. We evaluated the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on the prevention of lung-carcinoma development using an intermittent smoking-induced lung-carcinoma mouse model. Additionally, we explored COX-2's role in lipid metabolism.

Methods

Male A/J mice were exposed to sham air or mainstream cigarette smoke for 20 weeks. Vehicle or celecoxib was administered via intragastric feeding once daily. Lung tissues were analyzed for tumor nodules and emphysema; the bronchoalveolar lavage fluid was collected for cell counting. COX-2 expression was measured using rea

SUBMITTER: Sakurai K 

PROVIDER: S-EPMC11961424 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature